CA2865620A1 - Multivalent vaccine protection from staphylococcus aureus infection - Google Patents

Multivalent vaccine protection from staphylococcus aureus infection Download PDF

Info

Publication number
CA2865620A1
CA2865620A1 CA2865620A CA2865620A CA2865620A1 CA 2865620 A1 CA2865620 A1 CA 2865620A1 CA 2865620 A CA2865620 A CA 2865620A CA 2865620 A CA2865620 A CA 2865620A CA 2865620 A1 CA2865620 A1 CA 2865620A1
Authority
CA
Canada
Prior art keywords
aureus
infection
subject
vaccine
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2865620A
Other languages
English (en)
French (fr)
Inventor
Mark Shirtliff
Janette HARRO
Jeffrey Leid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland, Baltimore
Original Assignee
University of Maryland, Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland, Baltimore filed Critical University of Maryland, Baltimore
Publication of CA2865620A1 publication Critical patent/CA2865620A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2865620A 2012-03-05 2013-03-05 Multivalent vaccine protection from staphylococcus aureus infection Abandoned CA2865620A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606750P 2012-03-05 2012-03-05
US61/606,750 2012-03-05
PCT/US2013/029053 WO2013134225A1 (en) 2012-03-05 2013-03-05 Multivalent vaccine protection from staphylococcus aureus infection

Publications (1)

Publication Number Publication Date
CA2865620A1 true CA2865620A1 (en) 2013-09-12

Family

ID=49117246

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865620A Abandoned CA2865620A1 (en) 2012-03-05 2013-03-05 Multivalent vaccine protection from staphylococcus aureus infection

Country Status (6)

Country Link
US (2) USRE48137E1 (enExample)
EP (1) EP2822582B1 (enExample)
JP (1) JP6204930B2 (enExample)
CA (1) CA2865620A1 (enExample)
ES (1) ES2642892T3 (enExample)
WO (1) WO2013134225A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
WO2015171693A1 (en) * 2014-05-06 2015-11-12 Virginia Commonwealth University A new target for firmicutes and related bacteria: the prp protease
CA3042015A1 (en) 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EP3600358A1 (en) * 2017-03-31 2020-02-05 Acell, Inc. Extracellular matrix compositions with bactericidal or bacteriostatic characteristics useful for protecting and treating patients with bacterial infections
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CA3204730A1 (en) * 2021-01-15 2022-07-21 Gowrishankar MUTHUKRISHNAN Staphylococcus aureus antigen-based nucleic acid vaccines
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2004018624A2 (en) 2002-08-20 2004-03-04 Chiron Corporation Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
EP2176662B1 (en) 2007-07-30 2012-03-28 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And Behalf Of Methods and devices for the detection of biofilm
US8318180B2 (en) 2008-09-30 2012-11-27 University Of Maryland, Baltimore Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens

Also Published As

Publication number Publication date
ES2642892T3 (es) 2017-11-20
EP2822582A4 (en) 2015-12-30
WO2013134225A1 (en) 2013-09-12
US9265820B2 (en) 2016-02-23
EP2822582A1 (en) 2015-01-14
JP6204930B2 (ja) 2017-09-27
USRE48137E1 (en) 2020-08-04
EP2822582B1 (en) 2017-09-13
US20150024000A1 (en) 2015-01-22
JP2015510883A (ja) 2015-04-13

Similar Documents

Publication Publication Date Title
USRE48137E1 (en) Multivalent vaccine protection from Staphylococcus aureus infection
JP6594385B2 (ja) 免疫原性組成物
Kurlenda et al. Alternative therapies in Staphylococcus aureus diseases
US8318180B2 (en) Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens
US9109036B2 (en) Immunogenic composition comprising alpha-hemolysin oligopeptides
US10174085B2 (en) Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
EP2476433A1 (en) Immunogenic composition
WO2013032964A1 (en) Compositions and methods for preventing and treating biofilms
EP2248533B1 (en) Polypeptide derived from enterococcus and its use for vaccination
JP2022084752A (ja) 環状抗微生物性擬ペプチド及びその使用
EP2450053B1 (en) Novel antigen of enterococcal pathogens and use thereof as vaccine component for therapy and/or prophylaxis
US20180141981A1 (en) Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
WO2022261360A1 (en) Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
US20220160857A1 (en) Multivalent vaccines derived from klebsiella out membrane proteins
US20090220538A1 (en) vaccine for staphylococcal infections
HK1146471B (en) Polypeptide derived from enterococcus and its use for vaccination

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180301

FZDE Discontinued

Effective date: 20210914